Home > Riviste > Italian Journal of Emergency Medicine > Fascicoli precedenti > Italian Journal of Emergency Medicine 2020 December;9(3) > Italian Journal of Emergency Medicine 2020 December;9(3):142-4

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

CASE REPORT   Openopen access

Italian Journal of Emergency Medicine 2020 December;9(3):142-4

DOI: 10.23736/S2532-1285.20.00028-2

Copyright © 2020 THE AUTHORS

This is an open access article under the CC BY-NC-ND license

lingua: Inglese

Acute respiratory distress syndrome in COVID-19: experience with cytokine inhibitors

Francesco S. SERINO 1 , Lucio BROLLO 2, Fabio TOFFOLETTO 3

1 Unit of Infectious Diseases, Department of Medicine, ASL 4 Veneto Orientale, Portogruaro, Venice, Italy; 2 Unit of Infectious Diseases, Department of Medicine, ASL 4 Veneto Orientale, Jesolo, Venice, Italy; 3 Unit of Anesthesia and Intensive Care, Critical Area Department, ASL 4 Veneto Orientale, Jesolo, Venice, Italy



Clinical manifestations of SARS-CoV-2 infection (COVID-19) are extremely variable. The severity of the clinical presentation picture is associated with the age and presence of comorbidity, although some unfavorable prognosis risk factors are not yet clearly recognized. We describe the case of a patient with ARDS undergoing currently available antiviral treatments, as well as drugs that inhibit the cytokine cascade, through clinical trials or compassionate uses. In our case the unexpected and subsequent use of two anti-IL-6 molecules allowed the inhibition of the cytokine cascade at different times contributing to the improvement of the outcomes.


KEY WORDS: COVID-19; Tocilizumab; Respiratory distress syndrome, adult

inizio pagina